Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 924.0	$ 2,326.5
Marketable securities	1,956.2	2,568.6
Accounts receivable, net	1,501.5	1,441.6
Due from anti-CD20 therapeutic programs	324.5	300.6
Inventory	921.6	1,001.6
Other current assets	1,231.9	1,093.3
Total current assets	6,859.7	8,732.2
Marketable securities	2,825.2	2,829.4
Property, plant and equipment, net	2,610.9	2,501.8
Intangible assets, net	4,103.9	3,808.3
Goodwill	3,611.7	3,669.3
Investments and other assets	1,184.5	1,335.8
Total assets	21,195.9	22,876.8
Current liabilities:
Current portion of notes payable and other financing arrangements	561.5	4.7
Taxes payable	70.0	231.9
Accounts payable	316.4	279.8
Accrued expenses and other	2,044.6	2,903.5
Total current liabilities	2,992.5	3,419.9
Notes payable and other financing arrangements	5,952.7	6,512.7
Deferred tax liability	94.5	93.1
Other long-term liabilities	688.8	722.5
Total liabilities	9,728.5	10,748.2
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	0.0
Accumulated other comprehensive loss	(325.2)	(319.9)
Retained earnings	14,781.2	15,071.6
Treasury stock, at cost	(2,977.1)	(2,611.7)
Total Biogen Inc. shareholders’ equity	11,479.0	12,140.1
Noncontrolling interests	(11.6)	(11.5)
Total equity	11,467.4	12,128.6
Total liabilities and equity	$ 21,195.9	$ 22,876.8